Combined Anterior Suprascapular Nerve Block and Superficial Cervical Plexus Block In Shoulder Arthroplasty Surgery

Application Of Combined Anterior Suprascapular Nerve Block and Superficial Cervical Plexus Block In Reverse Shoulder Arthroplasty Surgery, A Case Series

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06146179

Enrollment

Registered

2023-11-24

Start date

2023-11-01

Completion date

2024-05-30

Last updated

2024-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anterior Suprascapular Nerve Block, Diaphragmatic Paralysis, Phrenic Nerve Paralysis, Superficial Cervical Plexus Block

Keywords

diaphragmatic paralysis, anterior suprascapular nerve block, superficial cervical plexus block, reverse shoulder replacement, shoulder pain

Brief summary

The suprascapular nerve, originating from the C5 trunk, provides innervation to the acromioclavicular and glenohumeral joints. The supraclavicular nerve, a branch of the cervical plexus, contributes to the sensory innervation of the upper deltoid region. Cervical and brachial plexus blocks can cause diaphragm paralysis. This study examined the effects of low-volume combined anterior suprascapular nerve block and superficial cervical plexus block on pain and phrenic nerve in participants underwent reverse shoulder arthroplasty surgery.

Detailed description

A retrospective analysis was performed on data obtained from eight participants who underwent reverse shoulder arthroplasty surgery. Anterior suprascapular nerve block and superficial cervical plexus block were applied to these participants. Anterior suprascapular nerve block was performed using 5 ml and superficial cervical plexus block was performed using 3 ml of %0,5 bupivacaine. Ultrasound was used to measure the diaphragm thickness at the end of inspiration and expiration, and to calculate the diaphragm thickness fraction. Postoperative pain management included patient-controlled analgesia with morphine, opioid consumption and VAS score recorded by pain observation forms. Data will be collected by examining these pain observation forms and diaphragm thickness measurements.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Population is defined by database within a given time frame * Participants who underwent combined anterior suprascapular nerve block and superficial cervical plexus block in reverse shoulder arthroplasty surgery * Participants aged 18-80 * ASA I-II-III

Exclusion criteria

* ASA score \> III * Pediatric individuals under 18 years of age * Individuals who are pregnant * Known diaphragmatic paralysis * Had an allergy or toxicity to local anesthetic agents * Have an opioid drug allergy

Design outcomes

Primary

Measure	Time frame	Description
Postoperative Change Ratio of Diaphragm Thickness Fraction	Postoperatively 30th. min.	Postoperative Change Ratio of Diaphragm Thickness Fraction (%) at Postoperatively 30th. min.

Secondary

Measure	Time frame	Description
Pain Assessment with Visual Analogue Scale at postoperatively 30th. Min.	Postoperatively 30th. min	Postoperative VAS score (Ranging from 0-10)
Pain Assessment with Visual Analogue Scale at postoperatively 4th. Hours.	Postoperatively 4th. hour	Postoperative VAS score (Ranging from 0-10)
Pain Assessment with Visual Analogue Scale at postoperatively 6th. Hours.	Postoperatively 6th. hour	Postoperative VAS score (Ranging from 0-10)
Pain Assessment with Visual Analogue Scale at postoperatively 12th. Hours.	Postoperatively 12th. hour	Postoperative VAS score (Ranging from 0-10)
Pain Assessment with Visual Analogue Scale at postoperatively 24th. Hours.	Postoperatively 24th. hour	Postoperative VAS score (Ranging from 0-10)
Opioid Consumption at postoperatively 12th. Hours.	Postoperatively 12th. hour	Postoperative Opioid Consumption with Morphine PCA (0.5 mg/cc, demand dose 2 cc, lock of time; 10 min. )
Opioid Consumption at postoperatively 24th. Hours.	Postoperatively 24th. hour	Postoperative Opioid Consumption with Morphine PCA (0.5 mg/cc, demand dose 2 cc, lock of time; 10 min. )
Opioid Consumption at postoperatively 30th. Min.	Postoperatively 30th. min.	Postoperative Opioid Consumption with Morphine PCA (0.5 mg/cc, demand dose 2 cc, lock of time; 10 min. )
Opioid Consumption at postoperatively 4th. Hours.	Postoperatively 4th. hour	Postoperative Opioid Consumption with Morphine PCA (0.5 mg/cc, demand dose 2 cc, lock of time; 10 min. )
Opioid Consumption at postoperatively 6th. Hours.	Postoperatively 6th. hour	Postoperative Opioid Consumption with Morphine PCA (0.5 mg/cc, demand dose 2 cc, lock of time; 10 min. )

Other

Measure	Time frame	Description
Patient Satisfaction with 5 point Likert Patient Satisfaction scale at postoperatively 24th. Hours	Postoperatively 24th hour	Postoperative 24th. hour 5 point Likert Patient Satisfaction scale (1-Very dissatisfied, 2 - Dissatisfied, 3 - Unsure, 4 - Satisfied, 5 - Very satisfied)
Postoperative Nausea and Vomiting	During Postoperatively 24 hour	Postoperative Nausea and Vomiting Score ( PONV0: No Nausea, No vomiting; PONV1: Nausea present, No vomiting; PONV2: Nausea and vomiting present; PONV3: Vomiting\>2 epizodes in 30th. min; PONV4:Vomiting\>3 epizodes in 30th.min)

Countries

Turkey (Türkiye)

Outcome results